| 2.785 0.065 (2.39%) | 01-09 13:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.8 | 1-year : | 5.86 |
| Resists | First : | 4.11 | Second : | 5.01 |
| Pivot price | 3.94  |
|||
| Supports | First : | 2.65 | Second : | 2.2 |
| MAs | MA(5) : | 3.14 |
MA(20) : | 4.01 |
| MA(100) : | 4.79 |
MA(250) : | 3.86  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 4.1 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 8.53 | Low : | 1.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNLX ] has closed above bottom band by 0.9%. Bollinger Bands are 29% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3 - 3.02 | 3.02 - 3.03 |
| Low: | 2.62 - 2.63 | 2.63 - 2.65 |
| Close: | 2.69 - 2.72 | 2.72 - 2.74 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Fri, 09 Jan 2026
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances - RTTNews
Fri, 09 Jan 2026
H.C. Wainwright Maintains Genelux(GNLX.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛
Thu, 08 Jan 2026
Genelux Announces Underwritten Public Offering to Raise Capital - TipRanks
Thu, 08 Jan 2026
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Thu, 08 Jan 2026
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock - Quiver Quantitative
Thu, 08 Jan 2026
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock - Yahoo Finance Singapore
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 30.7 (%) |
| Shares Short | 3,080 (K) |
| Shares Short P.Month | 2,950 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -64.3 % |
| Return on Equity (ttm) | -123.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -3.15 |
| PEG Ratio | 0 |
| Price to Book value | 5.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|